Brief: NeuroVive And Yungjin Report Positive KL1333 Phase I Clinical Study Results

Abliva AB

21/05/2018 10:05

May 21 (Reuters) - NEUROVIVE PHARMACEUTICAL AB  NVP.ST :
    * NEUROVIVE AND YUNGJIN REPORTS POSITIVE KL1333 PHASE I
CLINICAL
STUDY RESULTS PAVING THE WAY FOR FURTHER CLINICAL DEVELOPMENT
    * STUDY IS EXPECTED TO COMMENCE IN SECOND HALF OF 2018.
    * REVIEW OF TOPLINE PHASE I DATA SHOWS THAT KL1333 HAS A
HIGHLY
FAVOURABLE AND VERY CLEAR DOSE-PROPORTIONAL PHARMACOKINETIC (PK)
PROFILE
    * STUDY WILL BE CONDUCTED AT SITES IN UK AND RESULTS ARE
EXPECTED
IN FIRST HALF OF 2019.
    * THERE WERE NO SERIOUS ADVERSE EVENTS (SAES)
    * ONLY MILD GASTROINTESTINAL ADVERSE EVENTS (AES) WERE
RECORDED AT
HIGHER DOSES

Source text for Eikon:  ID:nWkr9H2jqM 
Further company coverage:  NVP.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 587720920;))